ZBH
Zimmer Biomet Holdings, Inc. · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 91.62K | $4.55M | n/a | n/a |
| Q2 2026 | 158 | +1 | 160.27M | $13.80B | +8 | −6 |
| Q1 2026 | 159 | -2 | 157.26M | $14.21B | +8 | −11 |
| Q4 2025 | 160 | -1 | 174.74M | $15.72B | +3 | −3 |
| Q3 2025 | 25 | +3 | 107.43M | $10.58B | +3 | −1 |
| Q2 2025 | 20 | -3 | 103.64M | $9.45B | +2 | −5 |
| Q1 2025 | 20 | +3 | 59.00M | $6.68B | +3 | n/a |
| Q4 2024 | 17 | 0 | 58.85M | $6.22B | +1 | −1 |
| Q3 2024 | 16 | -2 | 46.04M | $4.97B | n/a | −2 |
| Q2 2024 | 18 | n/a | 44.34M | $4.81B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 16.75M | n/a | $1.82B | 1.1% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 12.51M | n/a | $1.36B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 3 | PRIMECAP Management ✦ | 5.05M | n/a | $548.57M | 0.4% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 4.75M | n/a | $514.49M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 2.21M | n/a | $239.75M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 649.13K | n/a | $70.45M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 490.14K | n/a | $53.19M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 8 | AQR Capital Management ✦ | 420.78K | n/a | $45.36M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 9 | Citadel Advisors ✦ | 376.48K | n/a | $40.86M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Bridgewater Associates ✦ | 351.57K | n/a | $38.16M | 0.2% | n/c | 1 | SEC ↗ |
| 11 | Millennium Management ✦ | 220.34K | n/a | $23.91M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | GAMCO Investors ✦ | 215.19K | n/a | $23.35M | 0.3% | n/c | 1 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 180.90K | n/a | $19.63M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 69.05K | n/a | $7.49M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 56.00K | n/a | $6.08M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 16 | Wellington Management ✦ | 33.01K | n/a | $3.58M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 17 | Fisher Asset Management ✦ | 5.23K | n/a | $567,653 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Capital World Investors ✦ | 2.77K | n/a | $300,411 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 908 holders, 191.49M shares, $15.84B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 5.69K sh · $528,978
Officer · 3.00K sh · $295,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology